2/27
01:00 am
ipha
Innate Pharma to Participate in the 2025 Leerink Partners Global Healthcare Conference
Medium
Report
Innate Pharma to Participate in the 2025 Leerink Partners Global Healthcare Conference
2/18
01:51 pm
ipha
Innate Pharma and Merus gets FDA Breakthrough Therapy Designation for their respective treatments [Seeking Alpha]
Medium
Report
Innate Pharma and Merus gets FDA Breakthrough Therapy Designation for their respective treatments [Seeking Alpha]
2/18
11:37 am
ipha
Innate's lacutamab gains FDA breakthrough therapy designation [Yahoo! Finance]
Medium
Report
Innate's lacutamab gains FDA breakthrough therapy designation [Yahoo! Finance]
2/17
01:20 am
ipha
Innate Pharma Announces U.S. FDA Granted Breakthrough Therapy Designation to Lacutamab for Relapsed or Refractory Sézary Syndrome [Yahoo! Finance]
High
Report
Innate Pharma Announces U.S. FDA Granted Breakthrough Therapy Designation to Lacutamab for Relapsed or Refractory Sézary Syndrome [Yahoo! Finance]
2/17
01:02 am
ipha
Innate Pharma Announces U.S. FDA Granted Breakthrough Therapy Designation to Lacutamab for Relapsed or Refractory Sézary Syndrome
High
Report
Innate Pharma Announces U.S. FDA Granted Breakthrough Therapy Designation to Lacutamab for Relapsed or Refractory Sézary Syndrome
2/6
08:13 am
ipha
Innate Pharma S.A. (NASDAQ: IPHA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $11.50 price target on the stock.
Low
Report
Innate Pharma S.A. (NASDAQ: IPHA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $11.50 price target on the stock.
1/31
03:40 pm
ipha
3 Promising Penny Stocks With Market Caps Under US$500M [Yahoo! Finance]
Neutral
Report
3 Promising Penny Stocks With Market Caps Under US$500M [Yahoo! Finance]
1/27
01:00 am
ipha
Innate Pharma Announces First Patient Dosed in Phase 1 Study of Its Nectin-4 Targeting Antibody Drug Conjugate IPH4502 in Selected Advanced Solid Tumors
Low
Report
Innate Pharma Announces First Patient Dosed in Phase 1 Study of Its Nectin-4 Targeting Antibody Drug Conjugate IPH4502 in Selected Advanced Solid Tumors
1/21
01:26 am
ipha
Innate Pharma Announces Nectin-4 Antibody Drug Conjugate Investor and Analyst Event in New York [Yahoo! Finance]
Medium
Report
Innate Pharma Announces Nectin-4 Antibody Drug Conjugate Investor and Analyst Event in New York [Yahoo! Finance]
1/21
01:00 am
ipha
Innate Pharma Announces Nectin-4 Antibody Drug Conjugate Investor and Analyst Event in New York
Medium
Report
Innate Pharma Announces Nectin-4 Antibody Drug Conjugate Investor and Analyst Event in New York
1/17
07:56 am
ipha
Innate Pharma S.A. (NASDAQ: IPHA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $11.50 price target on the stock.
Low
Report
Innate Pharma S.A. (NASDAQ: IPHA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $11.50 price target on the stock.
1/16
01:00 am
ipha
Number of Shares and Voting Rights of Innate Pharma as of December 31, 2024
Low
Report
Number of Shares and Voting Rights of Innate Pharma as of December 31, 2024
1/10
01:00 am
ipha
Innate Pharma Announces Transformative Strategy to Accelerate Growth
Low
Report
Innate Pharma Announces Transformative Strategy to Accelerate Growth
12/20
01:22 am
ipha
Innate Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Low
Report
Innate Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
12/20
01:00 am
ipha
Innate Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Low
Report
Innate Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference